L3MBTL1
MOLECULAR TARGETL3MBTL histone methyl-lysine binding protein 1
L3MBTL1 (L3MBTL histone methyl-lysine binding protein 1) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting L3MBTL1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 1.10 | 2 |
| 2 | DEAD-box RNA Helicases | 0.69 | 1 |
| 3 | Thioctic Acid | 0.69 | 1 |
| 4 | Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). | 0.69 | 1 |
| 5 | Cefotetan | 0.69 | 1 |
| 6 | Cefsulodin | 0.69 | 1 |
| 7 | Fusaric Acid | 0.69 | 1 |
| 8 | Picloram | 0.69 | 1 |
| 9 | streptonigrin | 0.69 | 1 |
| 10 | Thioctic Acid | 0.69 | 1 |
About L3MBTL1 as a Drug Target
L3MBTL1 (L3MBTL histone methyl-lysine binding protein 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented L3MBTL1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
L3MBTL1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.